Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Recursion Pharmaceuticals, Inc. (RXRX : NSDQ)

• Company Description    Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering. Recursion Pharmaceuticals Inc. is based in SALT LAKE CITY. Number of Employees: 800

• Price / Volume Information    Yesterday's Closing Price: $4.83 Daily Weekly Monthly 20 Day Moving Average: 15,440,485 shares Shares Outstanding: 434.15 (millions) Market Capitalization: $2,096.95 (millions) Beta: 0.91 52 Week High: $12.36 52 Week Low: $3.79 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.36% -15.87% 12 Week -5.48% -14.14% Year To Date -28.55% -35.94%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 41S RIO GRANDE STREET - SALT LAKE CITY,UT 84101 USA ph: 385-269-0203 fax: 801-821-2872 investor@recursion.com http://www.recursion.com

• General Corporate Information    Officers Christopher Gibson - Chief Executive Officer and Director Robert Hershberg - Chairman Ben Taylor - Chief Financial Officer Zachary Bogue - Director Blake Borgeson - Director Peer Information Recursion Pharmaceuticals, Inc. (CORR.) Recursion Pharmaceuticals, Inc. (RSPI) Recursion Pharmaceuticals, Inc. (CGXP) Recursion Pharmaceuticals, Inc. (BGEN) Recursion Pharmaceuticals, Inc. (GTBP) Recursion Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 75629V104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 434.15 Most Recent Split Date: (:1) Beta: 0.91 Market Capitalization: $2,096.95 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.48 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 17.76% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.28 Price/Cash Flow: - Price / Sales: 32.46 EPS Growth vs. Year Ago Period: -2.50% vs. Previous Quarter: 18.00% Sales Growth vs. Year Ago Period: 33.34% vs. Previous Quarter: 30.37% ROE 06/30/25 - -76.09 03/31/25 - -74.70 12/31/24 - -72.88 ROA 06/30/25 - -54.29 03/31/25 - -54.02 12/31/24 - -52.86 Current Ratio 06/30/25 - 3.58 03/31/25 - 4.11 12/31/24 - 3.81 Quick Ratio 06/30/25 - 3.58 03/31/25 - 4.11 12/31/24 - 3.81 Operating Margin 06/30/25 - -1,004.91 03/31/25 - -961.32 12/31/24 - -788.02 Net Margin 06/30/25 - -1,004.91 03/31/25 - -961.32 12/31/24 - -788.02 Pre-Tax Margin 06/30/25 - -1,004.88 03/31/25 - -962.17 12/31/24 - -789.93 Book Value 06/30/25 - 2.12 03/31/25 - 2.30 12/31/24 - 2.61 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.02 03/31/25 - 0.02 12/31/24 - 0.02 Debt-to-Capital 06/30/25 - 1.52 03/31/25 - 1.73 12/31/24 - 1.81

Powered by Zacks Investment Research ©